TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02389361
Drug: Paracetamol-Tramadol
Normalized name: tramadol and paracetamol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Postoperative analgesia with intravenous Paracetamol and Tramadol
Study: NCT03072147
Drug: Teriparatide
Normalized name: Teriparatide
DrugBank: Teriparatide (DB06285)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 20 mcg of teriparatide injected in thigh or abdomen once a day for 24 weeks.
Study: NCT03649763
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine 1%, distal ( ulnar and medial nerve): 6ml/nerve , 12m total
Study: NCT03649763
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bupivacaine 0.5%,distal ( ulnar and medial nerve): 6ml/nerve , 12m total
Study: NCT03649763
Drug: Lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: lidocaine 1%, distal and proximal ( ulnar and medial nerve): 3ml/nerve , 12m total
Study: NCT04584749
Drug: Lidocaine Iv
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2% lidocaine or 0.9% physiological saline will be used as placebo, and it will be administered as a bolus during anesthetic induction equivalent to 1.5 mg / kg of lidocaine. After induction, an intravenous infusion will be started at 0.1 ml / kg / h of the study preparation, equivalent to 2mg / kg / h of lidocaine.~20 ml syringe for induction and two 50 ml syringes for anesthetic maintenance containing 2% Lidocaine .
Study: NCT01923909
Drug: Intra-articular platelet-rich plasma
Normalized name: Platelet Rich Plasma
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular platelet-rich plasma This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the supra patellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
Study: NCT02452463
Drug: Nintedanib
Normalized name: Nintedanib
DrugBank: Nintedanib (DB09079)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01916720
Drug: SB-480848 40 mg
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug
Study: NCT01916720
Drug: SB-480848 80 mg
Normalized name: SB-649868
DrugBank: SB-649868 (DB14822)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study Drug
Study: NCT02213367
Drug: Bilastine
Normalized name: bilastine
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 20mg (8 weeks)
Study: NCT02213367
Drug: Bilastine
Normalized name: bilastine
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 40mg
Study: NCT02213367
Drug: Bilastin
Normalized name: Bilastina
DrugBank: Bilastine (DB11591)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 80mg
Study: NCT05907512
Drug: Endostar
Normalized name: Endostar
DrugBank: Endostar (DB11727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of 210 mg (14 vials) is administered by intravenous pump from Day 1 to Day 3 of each course, every 4 weeks as a cycle, until disease recurrence, metastasis or intolerable toxicity, and up to 6 courses of administration.
Study: NCT05907512
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 mg/kg by intravenous drip every 2 weeks (Day 1 and Day 15 of each cycle) in a 4-week cycle until disease recurrence, metastasis, or intolerable toxicity for up to 1 year (about 13 cycles).
Study: NCT04437303
Drug: Continuation of oral anticoagulants
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral anticoagulant treatment will not be interrupted before the procedure.
Study: NCT04437303
Drug: Interruption of oral anticoagulants
Normalized name: OIL OF CAMPHOR
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peri-operative interruption of oral anticoagulants will be according to the Dutch guideline on antithrombotic therapy.~* For direct oral anticoagulant users this will be in general 48 hours before the procedure, except for Dabigatran users with renal insufficiency: with estimated glomerular filtration rate 50-80 mL/min/1.73m\^2 72 hours and with estimated glomerular filtration rate 30-50 mL/min/1.73m\^2 96 hours before procedure.~* For vitamin K antagonist users this will be 5 days for phenprocoumon and 3 days for acenocoumarol.~* After the procedure oral anticoagulants will be resumed after 24 hours, if deemed safe by the treating physician.
Study: NCT04041856
Drug: Povidone Ophthalmic
Normalized name: povidone ophthalmic
DrugBank: Povidone (DB11061)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Povidone-iodine 2% eye drop versus artificial tear drop for treatment of adenoviral keratoconjunctivitis
Study: NCT00023530
Drug: fluconazole
Normalized name: Fluconazole
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00023530
Drug: voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03505151
Drug: BI 409306 (C-13/N-15)
Normalized name: SODIUM NITRATE N-15
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: i.v solution
Study: NCT03505151
Drug: BI 409306
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film-coated tablet
Study: NCT01780610
Drug: estradiol and progesterone
Normalized name: ESTRADIOL/PROGESTERONE
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral estradiol, 2 mg, once daily, was introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness was greater than 7mm, progesterone 40-60 mg in oil was administered via intramuscular injection. Transfer of thawed embryos was performed 3 days later
Study: NCT01165450
Drug: Nexagon
Normalized name: NEXAGON
DrugBank: CODA-001 (DB14915)
Approvals — FDA: no, EMA: no, PMDA: no
Description: There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
Study: NCT03887884
Drug: CVT-301
Normalized name: CVT-6883
DrugBank: CVT-6883 (DB05936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa Inhalation Powder
Study: NCT03887884
Drug: Sinemet
Normalized name: Sinemet
DrugBank: Carbidopa (DB00190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single oral dose of Carbidopa/Levodopa 25 mg/100 mg
Study: NCT03363555
Drug: SHR-1210
Normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A humanized monoclonal immunoglobulin.
Study: NCT02716311
Drug: Afatinib
Normalized name: Afatinib
DrugBank: Afatinib (DB08916)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02716311
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00414180
Drug: Bupropion SR
Normalized name: Bupropion Hydrochloride 100 MG Oral Tablet, Extended Release, 12 HR [BUPROPION SR]
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01554410
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly infusion of 40 mg/m2 x 5 weeks (70 mg maximum)
Study: NCT01554410
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Weekly infusion x 5 weeks at escalating dose levels (50mg/m2, 75mg/m2, 100mg/m2, and 125mg/m2)
Study: NCT02220049
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01748344
Drug: Cetirizine
Normalized name: Cetirizine
DrugBank: Cetirizine (DB00341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10mg tablets
Study: NCT01704378
Drug: biphasic insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
Study: NCT01748344
Drug: High dose ONO-4053
Normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental
Study: NCT01748344
Drug: Low dose ONO-4053
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Experimental
Study: NCT01730846
Drug: Doxazosin 4mg/day
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
Study: NCT01730846
Drug: Doxazosin 8mg/day
DrugBank: Doxazosin (DB00590)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
Study: NCT01296607
Drug: Urocortin 2
Normalized name: Urocortin 2
DrugBank: Urocortin-2 (DB13033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 4a: Onset/Offset protocol: (Visits 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 in the presence of a saline washout between each dose.~Urocortin 2 will be infused at 3.6, 12, 36 and 120 pmol/min (15, 50, 150 and 498 nanograms/min) to achieve estimated end-organ concentrations of 0.6, 2, 6 and 20 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 2 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of urocortin 2 on repeated dosing. The doses used for this protocol will be identical to Protocol a.
Study: NCT01296607
Drug: Urocortin 3
Normalized name: Urocortin 2
DrugBank: Urocortin-2 (DB13033)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocol 4a: Onset/ Offset protocol: (Visit 1 or 3)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 or Urocortin 3 in the presence of a saline washout between each dose.~Urocortin 3 will be infused at 1200, 3600, 12000 and 36000 pmol/min (5, 15, 50 and 150 micrograms/min) to achieve estimated end organ concentrations of 199, 600, 2000 and 6000 micrograms/L respectively.~Protocol 4b: Reproducibility protocol (Visit 2 or 4)~Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 3 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of 3 on repeated dosing. The doses used for this protocol will be identical to Protocol a.
Study: NCT04454307
Drug: Tramadol
Normalized name: Tramadol
DrugBank: Tramadol (DB00193)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: tramadol 100 mg twice daily for 10 days
Study: NCT03336580
Drug: PRX004
Normalized name: Immunoglobulin G1, anti-(human transthyretin) (human-Mus musculus monoclonal PRX004 γ1-chain), disulfide with human-Mus musculus monoclonal PRX004 κ-chain, dimer
DrugBank: Coramitug (DB19411)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRX004 (0.1, 0.3, 1, 3, 10, and 30 mg/kg) IV every 28 days~PRX004 IV every 28 days at RP2D(s)~PRX004 IV every 28 days at RP2D(s)
Study: NCT03809052
Drug: GB1211
Normalized name: GB1211
DrugBank: GB1211 (DB17499)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hard capsules for oral use
Study: NCT00705198
Drug: Temozolomide (for newly diagnosed malignant glioma)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide treatment for newly diagnosed malignant glioma. The usual dose for adults in combination with radiotherapy is 75 mg/m2 orally once daily for 42 consecutive days. After a 4 week rest period, monotherapy at 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle is administered. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules.
Study: NCT01950234
Drug: ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acthar gel
Study: NCT02584608
Drug: ACTIMMUNE
Normalized name: Actimmune
DrugBank: Interferon gamma-1b (DB00033)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004398
Drug: heme arginate
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00004398
Drug: tin mesoporphyrin
Normalized name: Tin mesoporphyrin
DrugBank: Stannsoporfin (DB04912)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01473173
Drug: CJ-12420
Normalized name: CJ-12420
DrugBank: Tegoprazan (DB16690)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01473173
Drug: Esomeprazole 40mg
Normalized name: esomeprazole 40 MG
DrugBank: Esomeprazole (DB00736)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02082808
Drug: DTG
Normalized name: Dolutegravir
DrugBank: Dolutegravir (DB08930)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DTG is provided as 9 millimetre white, film-coated, round tablets debossed with SV 572 on one side and 50 on the other side
Study: NCT02082808
Drug: DCV
Normalized name: DCV
DrugBank: AV-COVID-19 (DB15802)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DCV is provided as a plain, green, biconvex, pentagonal film-coated tablet
Study: NCT00091910
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02496949
Drug: Icaritin
Normalized name: Icaritin
DrugBank: Icaritin (DB12672)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
Study: NCT01018862
Drug: Azelastine hydrochloride nasal spray 0.15%
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
Study: NCT01018862
Drug: Azelastine hydrochloride nasal spray 0.10%
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
Study: NCT00705198
Drug: Temozolomide (for relapsed malignant glioma)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide treatment for relapsed malignant glioma. The usual dose for adults is 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.~Temozolomide is administered as 20 mg and 100 mg capsules.
Study: NCT01976923
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: A sterile lid speculum is used to separate the lids. A subconjunctival injection of 1% lidocaine is applied to the inferotemporal quadrant. A 5% povidone iodine solution is used to disinfect the entire conjunctival surface. 1.25 mg / 0.05 mL of bevacizumab is injected using a 30-gauge needle inserted through the inferotemporal pars plana 3.5 mm from the limbus.
Study: NCT01385020
Drug: Gemfibrozil & red yeast rice (LipoCol)
DrugBank: Gemfibrozil (DB01241)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects.
Study: NCT00664248
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical application for 12 weeks
Study: NCT01222234
Drug: Cholecalciferol - CKD
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
Study: NCT01222234
Drug: Cholecalciferol - non-CKD
Normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
Study: NCT03578497
Drug: IL-1 receptor antagonist Anakinra
Normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IL-1 receptor antagonist Anakinra is a recombinant, non-glycosylated form of the human IL-1Ra in a 100 mg/ 0.67 ml solution for subcutaneous injection. Standard dosage licensed by the FDA and European Medicines Agency (EMA) is 100 mg Anakinra daily. It is supplied in single use prefilled glass syringes with 27 gauge needles as a sterile, clear, colourless-to-white, preservative free solution for daily s.c. administration.
Study: NCT02708251
Drug: glyceryl trinitrate cream
Normalized name: glyceryl trinitrate
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02708251
Drug: lidocaine cream
Normalized name: Neomycin and Polymyxin B Sulfates and Lidocaine Cream
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01396005
Drug: boceprevir
Normalized name: Boceprevir
DrugBank: Boceprevir (DB08873)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: boceprevir 800 mg (4 x 200 mg capsules), orally, every 8 hours, Day 2 through Day 7
Study: NCT01396005
Drug: methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: methadone, 20-150 mg tablets, liquid, or disket, orally, once per day, Day 1 through Day 8
Study: NCT01396005
Drug: buprenorphine/naloxone
Normalized name: BUPRENORPHINE/NALOXONE
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: buprenorphine/naloxone 8/2-24/6 mg, tablets, sublingual, once per day, Day 1 through Day 8
Study: NCT01777152
Drug: brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
Study: NCT01777152
Drug: prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
Study: NCT01777152
Drug: vincristine
Normalized name: Vincristine
DrugBank: Vincristine (DB00541)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
Study: NCT03264430
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: an antagonist of the NMDA receptor
Study: NCT03264430
Drug: bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: local anaesthetic
Study: NCT03164382
Drug: Sorafenib 200Mg Tab
Normalized name: SORAFENIB 200MG TAB
DrugBank: Sorafenib (DB00398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sorafenib will be administered orally at the starting dose of 400 mg twice daily (800 mg total daily dose) to patients randomized to Arm S in accordance to its package insert or equivalent documentation. The 400 mg dose will be achieved by administration of 2 x 200 mg film-coated tablets, administered twice daily.
Study: NCT00820534
Drug: Penciclovir
Normalized name: Penciclovir
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Penciclovir every 2 hours during waking hours for 96 hours
Study: NCT02439138
Drug: GS-1101
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral twice daily for 6 months followed by once daily until disease progression or unacceptable toxicity.
Study: NCT03073850
Drug: Antiplatelet
Normalized name: simethicone
DrugBank: Simethicone (DB09512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASA or clopidogrel
Study: NCT03073850
Drug: Low dose oral anticoagulant
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Edoxaban of 30mg
Study: NCT03591991
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: After randomization,the treatment started 30 minutes before PCI with a dose of 10 mg empagliflozin . After admission, patients were treated with 10 mg empagliflozin once daily for 3 mouths.
Study: NCT02450136
Drug: pazopanib
Normalized name: Pazopanib
DrugBank: Pazopanib (DB06589)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02652884
Drug: phosphate and betamethasone acetate, 2 mL.
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single dose of intramuscular depot corticosteroid
Study: NCT04405375
Drug: gemcitabin
Normalized name: Gemcitabin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1.25g/㎡ d1, repeated every 21 days
Study: NCT04405375
Drug: Pegaspargase
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2500IU/㎡ d1, total dose=\<3750IU, repeated every 21 days
Study: NCT04405375
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 75mg/㎡ d1-3, repeated every 21 days
Study: NCT04405375
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20mg d1-4
Study: NCT00554203
Drug: Sulfasalazine
Normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sulfasalazine 2 grams daily for 6 weeks
Study: NCT02005757
Drug: Bredinin tablet 150mg
Normalized name: BREDININ
DrugBank: Mizoribine (DB12617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bredinin 150mg qd vs Bredinin 50mg tid
Study: NCT02005757
Drug: Bredinin tablet 50mg
Normalized name: BREDININ
DrugBank: Mizoribine (DB12617)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bredinin 150mg qd vs Bredinin 50mg tid
Study: NCT00235079
Drug: Colchicine
Normalized name: Colchicine
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colchicine 0.5mg BID (\>70Kg) or 0.5 once daily for 6 months
Study: NCT02746744
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Infusion of Mabthera/Rituximab every 6 months
Study: NCT02746744
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
Study: NCT02746744
Drug: Sodium Chloride solution
Normalized name: ISOTONIC SODIUM CHLORIDE SOLUTION
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera